Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...
Clinical Trials Arena on MSN7d
Scholar Rock SMA drug shows muscle function benefitScholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal ...
MT Newswires on MSN5mon
Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist SaysThat came after Scholar Rock said its investigational drug, apitegromab, for spinal muscular atrophy met its primary endpoint ...
Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy ...
Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...
February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...
--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic ...
The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the stage for a pair of readouts with implications for weight loss research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback